-
-
-
-
-
-
-
Teva Pharma (TEVA) PT Raised to $45 at Truist Securities
-
-
-
-
-
-
-
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
-
-
-
-
-
-
-
Teva Reports Growth in Fourth Quarter and Full Year 2023
-
-
-
-
-
-
-
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
-
-
-
-
-
-
-
Teva Pharma (TEVA) and MedinCell Announce FDA Approval of UZEDY
-
-
-
-
-
-
-
Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States
-
-
-
-
-
-
-
Teva Reports Third Quarter 2022 Financial Results
-
1,160,146 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

